Nikeshan Jeyakumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nikeshan Jeyakumar has a total of 213 co-authors. Here are the top co-authors by number of shared publications:
- Lori Muffly
Stanford University, Stanford, California, United States
33 shared publications - Anne Marijn Kramer
Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California
26 shared publications - Crystal L. Mackall
Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
26 shared publications - David Bernard Miklos
Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
26 shared publications - Hrishikesh Krishna Srinagesh
Stanford University School of Medicine
26 shared publications - Sneha Ramakrishna
Stanford University
26 shared publications
Latest Publications
- Open Access
- 25 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 5821-5827
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Brexucabtagene-autoleucel (brexu-cel) produces high rates of measurable residual disease-negative (MRD-) complete response (CR) in adults with Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL); however, subsequent relapses remain frequent. It is unclear whether maintenance with tyrosine kinase inhibitors (TKIs) can enhance remission durability. We evaluated outcomes among adults with relapsed/refractory Ph+ ALL who received commercial brexu-cel and achieved MRD- CR across 19 U.S. institutions. Considering TKI maintenance as a time-varying covariate, we analyzed outcomes based on receipt of subsequent TKI maintenance versus no maintenance. Patients receiving consolidative transplantation or non-TKI maintenance were excluded. Fifty-one patients were included: 20 received TKI maintenance and 31 received no maintenance. The use of TKI maintenance was associated with a significantly lower 1-year cumulative incidence of relapse (HR 0.12; 95% CI, 0.02-0.88; p=0.037) which translated into improved progression-free survival (PFS, HR 0.19; 95% CI, 0.04-0.85; p=0.029) and a trend towards improved overall survival (OS, HR 0.34; 95% CI, 0.07-1.62; p=0.18). There was no difference in non-relapse mortality (NRM, HR 0.83; 95% CI, 0.12-5.87; p=0.85). This real-world analysis supports the administration of TKI maintenance in Ph+ ALL following achievement of MRD- CR with brexu-cel as a strategy to improve PFS following chimeric antigen receptor T cell therapy.
- 25 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 5821-5827
Open AccessImproved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Brexucabtagene-autoleucel (brexu-cel) produces high rates of measurable residual disease-negative (MRD-) complete response (CR) in adults with Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL); however, subsequent relapses remain frequent. It is unclear whether maintenance with tyrosine kinase inhibitors (TKIs) can enhance remission durability. We evaluated outcomes among adults with relapsed/refractory Ph+ ALL who received commercial brexu-cel and achieved MRD- CR across 19 U.S. institutions. Considering TKI maintenance as a time-varying covariate, we analyzed outcomes based on receipt of subsequent TKI maintenance versus no maintenance. Patients receiving consolidative transplantation or non-TKI maintenance were excluded. Fifty-one patients were included: 20 received TKI maintenance and 31 received no maintenance. The use of TKI maintenance was associated with a significantly lower 1-year cumulative incidence of relapse (HR 0.12; 95% CI, 0.02-0.88; p=0.037) which translated into improved progression-free survival (PFS, HR 0.19; 95% CI, 0.04-0.85; p=0.029) and a trend towards improved overall survival (OS, HR 0.34; 95% CI, 0.07-1.62; p=0.18). There was no difference in non-relapse mortality (NRM, HR 0.83; 95% CI, 0.12-5.87; p=0.85). This real-world analysis supports the administration of TKI maintenance in Ph+ ALL following achievement of MRD- CR with brexu-cel as a strategy to improve PFS following chimeric antigen receptor T cell therapy.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 13 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 13 shows ROC curves for the two cytokine signature at D14 and D21
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 13 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 13 shows ROC curves for the two cytokine signature at D14 and D21
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 1 shows individual lab values over time for grade 2+ IECHS
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 1 shows individual lab values over time for grade 2+ IECHS
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 7 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Clinical manifestations of gr2+ CRS.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 7 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Clinical manifestations of gr2+ CRS.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 5 shows cellular composition of apheresis material (A) and infused products (B) by IECHS severity.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 5 shows cellular composition of apheresis material (A) and infused products (B) by IECHS severity.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 8 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 8 shows the individual laboratory and CAR T values for the patient with severe IECHS who underwent daily cytokine profiling.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 8 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 8 shows the individual laboratory and CAR T values for the patient with severe IECHS who underwent daily cytokine profiling.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Baseline characteristics of the cohort by disease.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Baseline characteristics of the cohort by disease.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 3 shows lab values over time in grade 2+ vs no IECHS by underlying malignancy
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 3 shows lab values over time in grade 2+ vs no IECHS by underlying malignancy
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 6 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Clinical manifestations of gr1 IEC-HS.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 6 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Clinical manifestations of gr1 IEC-HS.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 6 shows T cell phenotypes in the manufactured products of CD4 (A) and CD8 (B) T cells
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 6 shows T cell phenotypes in the manufactured products of CD4 (A) and CD8 (B) T cells